Gen released the top 10 pharmaceutical companies with the highest market value in 2017

There are many criteria for ranking pharmaceutical companies, such as annual sales or R & D investment Recently, genetic engineering & Biotechnology news (hereinafter referred to as Gen), the authoritative magazine in the field of biomedicine in the United States, ranked the "top 10 pharmaceutical companies with the highest market value in the world in 2017" The data is compiled from Gen as of November 9, non-U.S companies' data converted to the top 10 pharmaceutical companies in gen this year according to the exchange rate of that day created a market value of $1722 trillion, up 9.8% from $1568 trillion last year and 5.9% from $1626 trillion in 2015 This year's list includes nine of the top 10 companies in 2016 Johnson & Johnson won the first place in a row Last year's No 6 GlaxoSmithKline was worth 66.38 billion pounds ($87.29 billion) this year, down 16% from last year and out of the top 10 Eli Lilly and company, ranked 11th last year, replaced GlaxoSmithKline this year Among the top 10 pharmaceutical companies, except Merck & Co., the market value of other companies has increased over the same period last year On October 27, 2017, Merck & Co released its third quarter revenue data: down to $10.325 billion (down 2%) from $10.536 billion in the same quarter of 2016 Merck's sales fell 3% To a large extent, this is related to the loss of American exclusive market of cholesterol lowering drugs zetia (ezetimibe), Vytorin (ezetimibe / simvastatin), the competition of similar generic drugs of its antibiotic product Cubicin and anti-inflammatory drug REMICADE (infliximab) Alex philippidis, senior editor of gen, analyzed that biotechnology companies experienced too many disappointing research and clinical trial failures in the third quarter of this year, while traditional pharmaceutical companies mostly went better than biotechnology companies There are five main reasons behind the success: most of the best-selling drugs with sales exceeding US $1 billion continue to grow; Scott, the new head of FDA After Gottlieb took office, the new drug listing process was simplified and more new drugs were approved; the tax reduction policy implemented by trump government; the policy of trump government to reduce the price of prescription drugs has not yet been implemented; the pharmaceutical enterprises have made remarkable achievements in turning from large-scale M & A to small-scale "flash" acquisition.